about
The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic fluxGalectin-9 activates and expands human T-helper 1 cells.Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity.C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicityTargeted induction of apoptosis for cancer therapy: current progress and prospects.EpCAM-targeted induction of apoptosis.EpCAM in morphogenesis.Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.Review: on TRAIL for malignant glioma therapy?Antibody-based fusion proteins to target death receptors in cancer.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.The ever-expanding immunomodulatory role of calreticulin in cancer immunityCalreticulin, a therapeutic target?Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL).Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells.Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speciExceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats.CD20(+) T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer.Editorial: Endoplasmic Reticulum and Its Role in Tumor Immunity.A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.Bifunctional antibody fragment-based fusion proteins for the targeted elimination of pathogenic T-cell subsets.Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5.A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity.Direct and Indirect Rituximab-Induced T Cell Depletion: Comment on the Article by Mélet et alCD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic eliminationPotent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion proteinSelective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion proteinSelective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signalingA better TRAIL variant for tumor cell-specific targeting? - letter
P50
Q28607006-12F4636F-B638-4984-9E97-35F9CADA9C63Q34761415-9202A86F-91CD-4701-8514-1A3290F0E573Q35025948-DC8441FD-A145-433F-85A0-025A700AF1B7Q36211431-0116834B-9E46-4760-A8C0-BB5BC0B0D78CQ36517735-2990B00C-0008-4AD2-B335-B385A17378A2Q37175453-83149CDA-B159-495D-A3DE-84A583B6E9D6Q37175456-D13B39EB-3A58-44B1-B0D4-EA2BE9963875Q37650715-9B8CBD6F-8AB9-44D6-AD30-1033C107E313Q37681647-DFA7BFFE-2103-483C-80A8-0BA3B4054D7BQ37826841-9A799AC2-4B7C-451C-9022-01D2313FA0B1Q38120535-13141FF9-B2E6-4871-8943-C5D0478037AEQ38370365-C60EFF57-D24A-48CD-B88D-0DE33D5EDC74Q38766974-9F079890-532E-415D-90C2-104C6715FD62Q38969083-73608FD1-2A22-4B17-A386-E59FADA54E91Q39003293-193A0FDD-B91F-4F0F-812B-0A26AC79264DQ39507204-D6E23B0D-62D2-4A9D-9CEC-15D1EF306431Q39629670-537C0511-FD80-4F79-A2E6-30CF2A6D6BDEQ39978504-12CE8ADB-1091-4021-944C-A3818C5EAD79Q40205104-2ADF4654-76D2-448E-BA7A-6B90D145DAC4Q40472879-E5277303-1A45-4422-BB78-75206544E9ADQ40490888-01575ABE-C3F8-49E3-84A2-30EC3E0B03E9Q40657165-971E11E5-3B18-406E-9E61-60E9CED6CAC6Q40773744-F8241A45-3DDA-41B9-94E8-39B92F941408Q41843709-BDF35A27-4B7A-41D0-8CCF-FC5F18AEB7F6Q46099770-DDA2ED9B-B35C-4C82-A153-4E02B1F3EBA2Q46805105-9251F761-3862-47F7-872C-0EE0D912FB76Q51750242-C43F852A-2666-4C0D-8200-3A4C98EEC4F7Q51829884-A69E700B-60FF-472D-B40F-22725378A30AQ53150906-3EBC4DB6-3DD2-4E8E-A0C0-A18137117D41Q54688579-7C4BF471-F015-407E-9744-18D48F837753Q57915749-274C3F68-48AE-40FE-BF89-D708F79303D7Q57939210-8D1ECCB1-456C-4CCF-929A-CA84111A901CQ64376217-57B6FC87-18C2-4BAD-83FE-58D096472722Q80706475-15190B87-920E-4B9E-864C-3A5862119902Q83937246-1189660B-AE17-4B57-97E6-54A774BC9E9DQ85160557-15714209-C0B6-483E-A3D2-30884C8F7BE4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Edwin Bremer
@ast
Edwin Bremer
@en
Edwin Bremer
@es
Edwin Bremer
@nl
Edwin Bremer
@sl
type
label
Edwin Bremer
@ast
Edwin Bremer
@en
Edwin Bremer
@es
Edwin Bremer
@nl
Edwin Bremer
@sl
prefLabel
Edwin Bremer
@ast
Edwin Bremer
@en
Edwin Bremer
@es
Edwin Bremer
@nl
Edwin Bremer
@sl
P1053
B-7508-2016
P106
P21
P31
P3762
P3829
P496
0000-0002-0325-7376